Grandma gives birth to her own grandchild

September 8, 2012

Cindy

Chicago, September 8: ?Setting foot in a hospital again, Emily and Mike Jordan couldn't help but feel anxious.

More than two years before, at age 29, Emily had been diagnosed with cervical cancer. But just before she was to undergo a radical hysterectomy, she was told that she was pregnant.

Faced with saving her own life or their unborn child's, the young couple made the excruciating decision to go forward with her surgery. It meant losing the baby, and forfeiting any chance at having their own children.

Or so they thought.

“I can't describe what that was like after finding out you have cancer, after finding out your chance of ever carrying a baby is gone,” Emily says, still stammering at times as she recounts that painful day in 2010.

Simply put, her body no longer had a place where a baby could grow.

But now, more than two years later, she and Mike had come from their suburban Chicago home to the labour and delivery department of a downtown hospital to realise the dream they thought was lost — to become parents, though not the way they, or most people, would have imagined.

Alongside them that day was Emily's mother, Cindy Reutzel — a fit, silver-haired 53-year-old grandmother whose profile revealed a round belly, a pregnant belly.

Reutzel was about to give birth to her own grandchild.

Just 34 years ago, Louise Brown, the first “test tube” baby, was born in Great Britain. The result? A veritable in-vitro baby boom.

It started with would-be mothers in their 20s and 30s. “Then people started pushing the envelope,” says Dr Helen Kim, director of the in vitro

fertilisation programme at the University of Chicago. “If you could help a menopausal woman in her 30s, could you help a menopausal woman in her 40s? And then it became, ‘Can you help a menopausal woman in her 50s?'

“And the answer is yes.”

Some older women were having their own babies. But more often, they were using egg donors to have their own children, or serving as surrogates or “gestational carriers”.

There was the 51-year-old grandmother in Brazil who gave birth to her twin grandchildren in 2007. There've been others, grandmothers in their 40s or 50s and even 60s.

Cindy Reutzel, Emily's mom, had a vague recollection of those stories. So when doctors shared the good news that they had been able to keep Emily's ovaries intact, Reutzel immediately made the offer.

“What if I carried your baby for you?” she asked.

Emily and Mike didn't take it too seriously at first. “We didn't really think that was a realistic option,” says Emily, who works in hospital administration.

It turned out, though, that it wasn't really that far-fetched after all, particularly for a young grandmother who's in good health, like Reutzel.

After a process that included psychological evaluation and hormonal manipulation to prepare their bodies, Kim eventually implanted Reutzel's uterus with an embryo created with an egg from Emily and Mike's sperm.

It was no easy process, with a regimen of hormonal shots. Work schedules were interrupted and vacations postponed. But Reutzel was committed.

“The thought of Emily and Mike not being able to have children and share that piece of their lives with someone just broke my heart,” says Reutzel, who lives in Chicago and is executive director at medical foundation. “I want Emily to have that connection with another human being like I had with her.”

As her belly grew, people started asking about “her baby”. But she was quick to tell them the story. This was not her baby, she was Grandma.

Admittedly, she says, she worried about the physical toll pregnancy might take, though her body handled it better than she expected. She also wondered how well she'd bounce back from a Caesarean section. That's how she had delivered Emily and her older brother, but that had been three decades ago.

Still, she reassured Emily and Mike throughout the pregnancy that the baby was fine, she was fine, everything would be fine.

Humour helped. Mike often teased his mother-in-law each time they'd take her to dinner or do something nice for her.

“Are we even yet?” he'd ask.

“Not yet,” she'd reply, laughing.

In truth, Mike and Emily knew there'd really be no way to repay this kind of gesture.

“This is a continuation of everything that she has done her entire life for me, which is to make sure that I have the best life possible,” Emily says.

All they could do, they said, was to promise to raise their baby as best they could. And that was enough for Reutzel.

“I know I gave a gift,” she says. “But I'm also getting so much in return.”

Last week, a few days after Emily's 32nd birthday, daughter sat next to mother, holding hands in the delivery room.

And Elle Cynthia Jordan was born.

“She looks just like you! She looks just like you!” Emily shouted, running from the delivery room to introduce their newborn to Mike.

Reutzel is recovering well. She even says she'd consider doing it again.

“When I watch both of them hold that baby and look into her face, it's like everything I could have imagined wanting for them — better than I could have imagined,” she says, her eyes filling with tears.

“This is what it was all about for me.”

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 29,2020

Doha, Feb 29: The United States signed a landmark deal with the Taliban on Saturday, laying out a timetable for a full troop withdrawal from Afghanistan within 14 months as it seeks an exit from its longest-ever war.

President Donald Trump urged the Afghan people to embrace the chance for a new future, saying the deal held out the possibility of ending the 18-year conflict.

"If the Taliban and the government of Afghanistan live up to these commitments, we will have a powerful path forward to end the war in Afghanistan and bring our troops home," he said on the eve of the event in Doha.

Secretary of State Mike Pompeo arrived in the Qatari capital to witness the signing of the accord, while Defence Secretary Mark Esper was in Kabul for a separate joint declaration with the Afghan government.

The agreement is expected to lead to a dialogue between the Kabul government and the Taliban that, if successful, could ultimately see the Afghan war wind down.

But the position of the Afghan government, which has been excluded from direct US-Taliban talks, remains unclear and the country is gripped by a fresh political crisis amid contested election results.

The United States and its allies will withdraw all their forces from Afghanistan within 14 months if the Taliban abide by the Doha agreement, Washington and Kabul said in a joint statement.

After an initial reduction of troops to 8,600 within 135 days of Saturday's signing, the US and its partners "will complete the withdrawal of their remaining forces from Afghanistan within 14 months... and will withdraw all their forces from remaining bases", the declaration stated.

The Doha accord was drafted over a tempestuous year of dialogue marked by the abrupt cancellation of the effort by Trump in September.

The signing comes after a week-long, partial truce that has mostly held across Afghanistan, aimed at building confidence between the warring parties and showing the Taliban can control their forces.

NATO Secretary General Jens Stoltenberg heralded the agreement as a "first step to lasting peace".

"The way to peace is long and hard. We have to be prepared for setbacks, spoilers, there is no easy way to peace but this is an important first step," the Norwegian former prime minister told reporters in Kabul.

Since the US-led invasion that ousted the Taliban after the September 11, 2001 attacks, America has spent more than $1 trillion in fighting and rebuilding in Afghanistan.

About 2,400 US soldiers have been killed, along with unknown tens of thousands of Afghan troops, Taliban fighters and Afghan civilians.

The insurgents said they had halted all hostilities Saturday in honour of the agreement.

"Since the deal is being signed today, and our people are happy and celebrating it, we have halted all our military operations across the country," Taliban spokesman Zabihullah Mujahid told AFP.

Close to 30 nations were represented at Saturday's signing in the Qatari capital.

While Kabul will not be represented at the Doha ceremony, set for 1245 GMT, it will send a six-person taskforce to the Qatari capital to make initial contact with the Taliban political office, established in 2013.

Any insurgent pledge to guarantee Afghanistan is never again used by jihadist movements such as Al-Qaeda and the Islamic State group to plot attacks abroad will be key to the deal's viability.

The Taliban's sheltering of Al-Qaeda was the main reason for the US invasion following the 9/11 attacks.

The group, which had risen to power in the 1990s in the chaos of civil war, suffered a swift defeat at the hands of the US and its allies. They retreated before re-emerging to lead a deadly insurgency against the new government in Kabul.

After the NATO combat mission ended in December 2014, the bulk of Western forces withdrew from the country, leaving it in an increasingly precarious position.

While Afghans are eager to see an end to the violence, experts say any prospective peace will depend on the outcome of talks between the Taliban and the Kabul government.

But with President Ashraf Ghani and rival Abdullah Abdullah at loggerheads over contested election results, few expect the pair to present a united front, unlike the Taliban, who would then be in a position to take the upper hand in negotiations.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
March 27,2020

London, Mar 27:  British Prime Minister Boris Johnson said Friday he has tested positive for the new coronavirus, but remains in charge of the U.K.'s response to the outbreak.

Johnson's office said he was tested on the advice of the chief medical officer after showing mild symptoms.

It said Johnson is self-isolating at his 10 Downing St. residence and continuing to lead the country's response to COVID-19.

In a video message, Johnson said he had a temperature and a persistent cough.

Over the last 24 hours I have developed mild symptoms and tested positive for coronavirus.

I am now self-isolating, but I will continue to lead the government’s response via video-conference as we fight this virus.

Together we will beat this. #StayHomeSaveLives pic.twitter.com/9Te6aFP0Ri

— Boris Johnson #StayHomeSaveLives (@BorisJohnson) March 27, 2020
"Be in no doubt that I can continue, thanks to the wizardry of modern technology, to communicate with all my top team, to lead the national fightback against coronavirus."

Earlier this week Britain’s Prince Charles announced that he had tested positive for the virus.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.